CAR-NK therapy focused on EGFRvIII and HER2 as its target molecules in GBM treatment, where intravenous injection into mice carrying subcutaneous EGFRvIII-positive GBM xenografts inhibited tumor growth and extended OS [182]. Here, ERBB2 is linked to neoplasm.